Change over period: —
NSE · ERIS
ERIS
-21.4% from the 52-week high · +22.1% above the low
Eris Lifesciences Ltd. engages in the provision of pharmaceutical products. The company is headquartered in Ahmedabad, Gujarat. The company went IPO on 2017-06-29. The Company’s manufacturing plant is located in Guwahati, Assam. Its therapeutic areas include oral diabetes care, cardiac care, pain/analgesics, gynecology, gastrointestinal, central nervous system (CNS), and vitamins, minerals and nutrients (VMN). The firm's brands include Glimisave, Eritel, Renerve, Tendia, Olmin, Rabonik, Tayo, Cyblex, Lnbloc, Remylin, Zomelis, Crevast, Atorsave, Ginkocer and Metital. The Company’s wholly owned subsidiaries include Kinedex Healthcare Private Limited, Aprica Healthcare Limited and Eris Healthcare Private Limited.
The short version. ERIS reported revenue of ₹892 crore for Sep 2026, up 12.6% from a year earlier. Net profit was ₹184 crore (up 53.3% year on year). Return on equity was 15.9% in Mar 2026. Promoter holding was 54.74% in Sep 2026, down 0.12 points over 8 quarters.
1 · The price
How has the stock traded?
ERIS trades 21.4% below its 52-week high and 22.1% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹892 cr.
Sep 2026 net profit of ₹184 cr.
5.4 pts higher than a year earlier.
Revenue compounded at 22.8% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 892 | 873 | 757 | 807 | 792 | 773 | 705 | 727 |
| Net profit | 184 | 142 | 282 | 100 | 120 | 118 | 94 | 84 |
| Net margin % | 20.6 | 16.3 | 37.2 | 12.3 | 15.2 | 15.3 | 13.3 | 11.5 |
| EPS (₹) | 13.25 | 10.28 | 20.33 | 7.32 | 8.82 | 8.66 | 6.89 | 6.14 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3129 | 2894 | 2009 | 1685 | 1347 | 1212 | 1074 | 982 |
| Net profit | 620 | 352 | 392 | 382 | 406 | 355 | 297 | 291 |
| Net margin % | 19.8 | 12.2 | 19.5 | 22.7 | 30.1 | 29.3 | 27.6 | 29.6 |
| EPS (₹) | 44.72 | 25.84 | 28.82 | 28.1 | 29.88 | 26.16 | 21.84 | 21.15 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 15.9% in Mar 2026; debt to equity is 0.59.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 15.9 | 12.3 | 15.2 | 17.4 |
| Return on capital % | 15.7 | 12.7 | 11.4 | 13.4 |
| EBITDA margin % | 35.4 | 35.6 | 34.4 | 32.3 |
| Net margin % | 19.8 | 12.1 | 19.3 | 22.5 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 22.8% | 20.8% |
| Profit CAGR | 17.5% | 11.8% |
4 · The owners
Who holds it, and are they adding?
Down 0.12 pts over 8 quarters.
Down 2.61 pts over 8 quarters.
Up 2.14 pts over 8 quarters.
+12 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 54.86 | 54.85 | 54.83 | 54.85 | 54.85 | 53.92 | 54.14 | 54.74 | -0.12 |
| FII | 8.35 | 8.43 | 8.4 | 7.21 | 6.85 | 6.39 | 5.75 | 5.74 | -2.61 |
| DII | 18.06 | 18.07 | 18.17 | 19.36 | 20.32 | 20.35 | 20.72 | 20.2 | +2.14 |
| Public | 18.72 | 18.66 | 18.59 | 18.57 | 17.99 | 19.33 | 19.4 | 19.32 | +0.6 |
Mutual fund holdings · Oct 2026
60 schemes hold this stock
48 the month before.
- Motilal Oswal Innovation Opportunities Fund3.15% of NAV
- Bank of India Consumption Fund2.59% of NAV
- Bandhan Healthcare Fund2.49% of NAV
- Mirae Asset Healthcare Fund2.27% of NAV
- Franklin India Small Cap Fund2.08% of NAV
- Bank of India Large & Mid Cap Fund2.01% of NAV
- Bank Of India Multi Cap FUND1.93% of NAV
- HDFC Small Cap Fund1.92% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for ERIS are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about ERIS
What is the ERIS share price?
ERIS (ERIS) last closed at ₹1,329.00, down 0.61% on the day. Its 52-week range is ₹1,095.50 to ₹1,701.30.
What is the market cap of ERIS?
ERIS has a market capitalisation of about ₹18,587 crore. Its price-to-earnings ratio is 26.3.
How are ERIS's latest results?
ERIS reported revenue of ₹892 crore for Sep 2026, up 12.6% from a year earlier. Net profit was ₹184 crore (up 53.3% year on year). Return on equity was 15.9% in Mar 2026. Promoter holding was 54.74% in Sep 2026, down 0.12 points over 8 quarters.
Who owns ERIS?
As of Sep 2026, shareholding was: Promoter 54.74%, FII 5.74%, DII 20.2%, Public 19.32%.
How many mutual funds hold ERIS?
60 mutual fund schemes held ERIS in October 2026. That compares with 48 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 29 May 2026 · Interim Dividend - Rs. 7.21
- 13 Feb 2025 · Interim Dividend - Rs. 7.35
- 11 Aug 2022 · Interim Dividend - Rs. 7.35
- 05 Aug 2021 · Interim Dividend - Rs. 6.01
- 13 Aug 2020 · Interim Dividend - Rs. 5.5
- 19 Mar 2020 · Interim Dividend - Rs. 2.87
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.